menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Investigating the Prevalence of Comorbidities in MS Clinical Trials

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    In 2016, an International Advisory Committee on Clinical Trials in Multiple Sclerosis (MS) recommended that comorbidities be more clearly and consistently described in enrolled clinical trial populations for common comorbidities so we can better understand the applicability of these trial findings to those in clinical practice. And so a recent study investigated the prevalence of comorbidities in MS clinical trial populations and found that 46 percent of the participants had one or more comorbid condition. Dive further into the findings from the study that was presented at the 2023 joint ECTRIMS-ACTRIMS meeting with Ashley Baker and Dr. Amber Salter, Associate Professor of Biostatistics at the University of Texas Southwestern Medical Center. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    In 2016, an International Advisory Committee on Clinical Trials in Multiple Sclerosis (MS) recommended that comorbidities be more clearly and consistently described in enrolled clinical trial populations for common comorbidities so we can better understand the applicability of these trial findings to those in clinical practice. And so a recent study investigated the prevalence of comorbidities in MS clinical trial populations and found that 46 percent of the participants had one or more comorbid condition. Dive further into the findings from the study that was presented at the 2023 joint ECTRIMS-ACTRIMS meeting with Ashley Baker and Dr. Amber Salter, Associate Professor of Biostatistics at the University of Texas Southwestern Medical Center. 

Facebook Comments

Schedule29 May 2024